Avinger logo
Avinger AVGR
report update icon

Quarterly report 2024-Q3
added 05-16-2026

Avinger Income Statement 2023-2011 | AVGR

Brief overview of revenue and earnings at Avinger

The conclusions below are based on five years of reported results. Avinger reported revenue of 7.9 million dollars in 2018 and 7.7 million dollars by 2023. The total change was −3.3%, with a CAGR of approximately −0.7%. The business did not achieve meaningful top-line expansion.

At the gross-profit level, the result moved from 1.4 million dollars to 2 million dollars, a change of +44.7%. The cost base moved more slowly than the top line, which supported margins. Gross profit as a share of revenue changed from 17.5% to 26.2%. The business retained more gross profit from each unit of revenue.

The five-year EBITDA result moved by +24.8%: from −21.7 million dollars to −16.3 million dollars. The operating result outpaced sales and points to improving efficiency. At the operating-margin level, the figure shifted from −274.8% to −213.6%. The increased EBITDA share is a positive sign.

The final result was −27.6 million dollars initially and −18.3 million dollars in the final year. The loss reduction is constructive, but the recovery is incomplete.

Over the period, capitalization shifted from $64.1 million to $2.6 million (−96%). Capitalization lags the underlying business improvement.

Summary assessment

Signs of deterioration dominate the five-year picture. The strongest signals are a stronger gross margin, higher operating efficiency and improving net profitability. The most visible risks are lower investor confidence, weak sales momentum and a narrow EBITDA buffer. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Avinger

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.59 M 1.38 M 42.5 M 21.7 M 165 M 64.1 M 949 M 12.3 B 2.06 T - - - -

Shares

786 K 417 K 4.72 M 2.46 M 7.24 M 1.07 M 652 K 414 K 11.4 M 241 K 234 K - -

Historical Prices

3.3 3.3 9 8.8 22.8 60 1.46 K 29.6 K 182 K - - - -

Net Income

-18.3 M -17.6 M -17.4 M -19 M -19.4 M -27.6 M -48.7 M -56.1 M -13.5 M -32 M -39.9 M -33.9 M -

Revenue

7.65 M 8.27 M 10.1 M 8.76 M 9.13 M 7.92 M 9.93 M 19.2 M 2.86 M 11.2 M 13 M 8.56 M -

Cost of Revenue

5.65 M 5.62 M 6.71 M 6.14 M 6.26 M 6.53 M 13 M 14.4 M 6.48 M 6.51 M 8.2 M - -

Gross Profit

2 M 2.65 M 3.42 M 2.62 M 2.87 M 1.38 M -3.07 M 4.77 M 1.05 M 4.7 M 4.76 M 4.41 M -

Operating Income

-16.6 M -16 M -18.1 M -17.4 M -19.4 M -23 M -42.6 M -50.7 M -40.7 M -25 M -37 M - -

Interest Expense

1.72 M 1.66 M 1.65 M 1.69 M 1.48 M 5.69 M 6.3 M 5.52 M 5.17 M 6.02 M 2.93 M - -

EBITDA

-16.3 M -15.8 M -17.4 M -16.5 M -18.5 M -21.7 M -41.1 M -49.2 M -39.4 M -23.6 M -35.5 M -33.1 M -

Operating Expenses

18.6 M 18.6 M 21.5 M 20 M 22.2 M 24.4 M 39.5 M 55.5 M 13.4 M 29.7 M 41.7 M 38.3 M -

General and Administrative Expenses

14.1 M 14.2 M 15.6 M 14.3 M 16.5 M 18.4 M 25.1 M 40 M 29.2 M 18.5 M 25.8 M 22.8 M -

All numbers in USD currency

Quarterly Income Statement Avinger

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

2.22 M 1.63 M 1.48 M 1.28 M 698 K 9.14 M 8.22 M 522 K 6.8 M 5.7 M 4.89 M 4.78 M 95.4 M 95.4 M 91.4 M 84.9 M 69.5 M 27.3 M 14.6 M 10.4 M 7.9 M 6.38 M 42.5 M 3.49 M 11.2 M 6.76 M 1.99 M 834 K 24.3 M 23.9 M 23.8 M 594 K 17.7 M 12.7 M 12.7 M 12.6 M 12.3 K 12.2 K 8.37 K 243 K 241 242 242 - - - - - - - - - - - -

Net Income

-3.71 M -4.36 M -5.52 M - -4.48 M -4.18 M -4.64 M - -4.09 M -4.21 M -5.14 M - -4.91 M -2.45 M -5.05 M - -4.52 M -4 M -5.85 M - -4.62 M -4.65 M -5.06 M - -5.39 M -5.8 M -10.3 M - -10.4 M -12.8 M -15.3 M -13.5 M -13 M -13.5 M -16.2 M -13.5 M -13.2 M -10.2 M -10.4 M -8.14 M -8.78 M -7.08 M -7.97 M - - - - - - - - - - - -

Revenue

1.65 M 1.85 M 1.86 M - 1.82 M 2.04 M 1.89 M - 2.25 M 2.13 M 1.89 M - 2.37 M 2.8 M 2.56 M - 2.3 M 1.47 M 2.26 M - 2.41 M 2.32 M 1.84 M - 2.02 M 2.06 M 1.81 M - 2.07 M 2.46 M 3.49 M 4.68 M 5.32 M 4.68 M 4.54 M 2.86 M 2.72 M 3.05 M 2.09 M 3.07 M 2.63 M 3.39 M 2.12 M - - - - - - - - - - - -

Cost of Revenue

1.22 M 1.47 M 1.52 M - 1.43 M 1.44 M 1.25 M - 1.46 M 1.48 M 1.36 M - 1.57 M 1.78 M 1.66 M - 1.52 M 1.11 M 1.76 M - 1.56 M 1.6 M 1.47 M - 1.48 M 2.17 M 1.42 M - 3.27 M 3.92 M 4.08 M - 3.74 M 3.64 M 3.36 M - 1.75 M 1.63 M 1.29 M - 1.47 M 1.97 M 1.5 M - - - - - - - - - - - -

Gross Profit

426 K 378 K 343 K - 388 K 605 K 636 K - 790 K 657 K 524 K - 800 K 1.02 M 894 K - 777 K 359 K 501 K - 847 K 720 K 373 K - 543 K -111 K 394 K - -1.2 M -1.46 M -584 K 981 K 1.57 M 1.04 M 1.18 M 1.05 M 971 K 1.41 M 800 K 1.5 M 1.16 M 1.42 M 616 K - - - - - - - - - - - -

Operating Income

-3.67 M -4.13 M -5.09 M - -4.03 M -3.73 M -4.26 M - -3.68 M -3.76 M -4.7 M - -4.49 M -4.41 M -4.65 M - -4.1 M -3.59 M -5.48 M - -4.62 M -4.71 M -5.03 M - -5.12 M -5.47 M -5.64 M - -8.87 M -11.3 M -13.8 M - -11.4 M -12.3 M -15 M - -9.88 M -9.08 M -9.42 M - -6.14 M -5.53 M -6.38 M - - - - - - - - - - - -

Interest Expense

48 K 234 K 416 K - 455 K 445 K 392 K - 407 K 440 K 439 K - 419 K 400 K 398 K - 433 K 414 K 398 K - 377 K 364 K 350 K - 324 K 362 K 4.67 M - 1.6 M 1.57 M 1.55 M - 1.55 M 1.24 M 1.17 M - 1.33 M 1.34 M 1.32 M - 1.71 M 1.62 M 1.57 M - - - - - - - - - - - -

EBITDA

-3.42 M -3.96 M -5.01 M - -3.82 M -3.59 M -4.19 M - -3.55 M -3.68 M -4.68 M - -3.96 M -4.04 M -4.46 M - -3.42 M -3.14 M -5.25 M - -3.96 M -4.28 M -4.83 M - -4.38 M -4.96 M -5.37 M - -7.71 M -10.4 M -13.4 M - -10.3 M -11.6 M -14.7 M - -8.92 M -8.44 M -9.11 M - -5.01 M -4.74 M -5.97 M - - - - - - - - - - - -

Operating Expenses

4.1 M 4.5 M 5.43 M - 4.42 M 4.33 M 4.89 M - 4.47 M 4.42 M 5.22 M - 5.29 M 5.42 M 5.54 M - 4.88 M 3.95 M 5.98 M - 5.46 M 5.43 M 5.4 M - 5.66 M 5.36 M 6.04 M - 7.67 M 9.8 M 13.2 M 12.9 M 13 M 13.3 M 16.2 M 13.4 M 10.8 M 10.5 M 10.2 M 8.48 M 7.31 M 6.95 M 7 M - - - - - - - - - - - -

General and Administrative Expenses

3.01 M 3.6 M 4.37 M - 3.38 M 3.35 M 3.54 M - 3.38 M 3.33 M 4.15 M - 3.89 M 3.92 M 3.94 M - 3.46 M 2.65 M 4.39 M - 4.09 M 4.09 M 3.99 M - 4.26 M 4.2 M 4.26 M - 4.93 M 6.19 M 9.32 M - 9.41 M 9.46 M 12.2 M - 6.89 M 6.54 M 6.36 M - 4.58 M 4.19 M 4.14 M - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Avinger (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.08 3.84 % $ 8.66 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.55 0.18 % $ 440 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.8 6.24 % $ 642 M israelIsrael
Electromed Electromed
ELMD
$ 29.6 0.27 % $ 245 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.71 0.69 % $ 12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.32 0.36 % $ 4.38 B britainBritain
LENSAR LENSAR
LNSR
$ 8.3 0.24 % $ 99.3 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.34 0.15 % $ 21.2 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.43 0.93 % $ 2.08 B usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 125.33 0.02 % $ 4.35 B usaUSA